EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prince Pharmaceutical Co's enterprise value is NT$1,341.5 Mil.
Prince Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$88.2 Mil. Therefore, Prince Pharmaceutical Co's EV-to-EBITDA for today is 15.21.
The historical rank and industry rank for Prince Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6935'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.7 Med: 14.75 Max: 19.24
Current: 15.21
During the past 5 years, the highest EV-to-EBITDA of Prince Pharmaceutical Co was 19.24. The lowest was 12.70. And the median was 14.75.
ROCO:6935's EV-to-EBITDA is ranked worse than 54.52% of 708
companies
in the Drug Manufacturers industry
Industry Median: 14.185
vs ROCO:6935: 15.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prince Pharmaceutical Co's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prince Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prince Pharmaceutical Co's EV-to-EBITDA falls into.
Prince Pharmaceutical Co's current Enterprise Value is NT$1,341.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prince Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$88.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prince Pharmaceutical Co (ROCO:6935) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Prince Pharmaceutical Co's PE Ratio for today is calculated as:
Prince Pharmaceutical Co's share price for today is NT$26.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prince Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Prince Pharmaceutical Co EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Prince Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Prince Pharmaceutical Co (ROCO:6935) Business Description
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6935 has been successfully added to your